ScholarLens Back to search
2012•Journal of Attention DisordersRequires access

Duloxetine in Adults With ADHD

Mathieu Bilodeau, Tarek Simon, Miriam H. Beauchamp, Paul Lespérance, Simon Dubreucq, Jean-Pierre Dorée, Smadar Valérie Tourjman

Open publisher page 24 citations

Abstract

OBJECTIVE: To assess the effect of duloxetine on ADHD in adults. METHOD: In a 6-week double-blind trial, 30 adults with ADHD received placebo or duloxetine 60 mg daily. The Conners' Adult ADHD Rating Scale (CAARS) and the Clinical Global Impression Scales (CGI) were used to assess symptom severity and clinical improvement. The Hamilton Anxiety Rating Scale (HARS) and the Hamilton Depression Rating Scale (HDRS) were used to measure the effect on anxiety and depressive symptoms. RESULTS: The Duloxetine group showed lower score on CGI-Severity at Week 6 (3.00 vs. 4.07 for placebo, p < .001), greater improvement on CGI-Improvement (2.89 vs. 4.00 at Week 6, p < .001), and greater decreases on five of eight subscales of the CAARS. There was no treatment group effect on HDRS or HARS scores. CONCLUSION: Duloxetine may be a therapeutic option for adults with ADHD, but further studies are required to replicate these findings in larger samples.

About this research paper

What this paper is about

OBJECTIVE: To assess the effect of duloxetine on ADHD in adults. METHOD: In a 6-week double-blind trial, 30 adults with ADHD received placebo or duloxetine 60 mg daily. The Conners' Adult ADHD Rating Scale (CAARS) and the Clinical Global Impression Scales (CGI) were used to assess symptom severity and clinical improvement. The Hamilton Anxiety Rating Scale (HARS) and the Hamilton Depression Rating Scale (HDRS) were used to measure the effect on anxiety and depressive symptoms. RESULTS: The Duloxetine group showed lower score on CGI-Severity at Week 6 (3.00 vs. 4.07 for placebo, p < .001), greater improvement on CGI-Improvement (2.89 vs. 4.00 at Week 6, p < .001), and greater decreases on five of eight subscales of the CAARS. There was no treatment group effect on HDRS or HARS scores. CONCLUSION: Duloxetine may be a therapeutic option for adults with ADHD, but further studies are required to replicate these findings in larger samples.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To assess the effect of duloxetine on ADHD in adults. METHOD: In a 6-week double-blind trial, 30 adults with ADHD received placebo or duloxetine 60 mg daily. The Conners' Adult ADHD Rating Scale (CAARS) and the Clinical Global Impression Scales (CGI) were used to assess symptom severity and clinical improvement. The Hamilton Anxiety Rating Scale (HARS) and the Hamilton Depression Rating Scale (HDRS) were used to measure the effect on anxiety and depressive symptoms. RESULTS: The Duloxetine group showed lower score on CGI-Severity at Week 6 (3.00 vs. 4.07 for placebo, p < .001), greater improvement on CGI-Improvement (2.89 vs. 4.00 at Week 6, p < .001), and greater decreases on five of eight subscales of the CAARS. There was no treatment group effect on HDRS or HARS scores. CONCLUSION: Duloxetine may be a therapeutic option for adults with ADHD, but further studies are required to replicate these findings in larger samples.

Key concepts: Duloxetine, Hamilton Anxiety Rating Scale, Clinical Global Impression, Rating scale, Psychology, Placebo, Anxiety, Depression (economics)

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Duloxetine in Adults With ADHD — Research Paper | ScholarLens